Full-Time

Director of Clinical Affairs Endoluminal

Posted on 8/22/2026

Intuitive Surgical

Intuitive Surgical

10,001+ employees

Manufactures robotic surgical systems and services

No salary listed

Sunnyvale, CA, USA

Hybrid

Three days on-site per week required.

PhD, MD, Master of Science (MS)

Category
Biology & Biotech (1)
Required Skills
Google Cloud Platform

Get referred to Intuitive Surgical

See people who can refer or advise you

Requirements
  • Advanced degree such as Doctor of Medicine, Master of Science or Doctor of Philosophy in scientific or biomedical engineering field with 8-12 years of experience in clinical affairs or research project management and at least 3-5 years of management experience
  • Relevant job experience combined with technical degree and/or master's degree may qualify
  • Previous experience assisting with the development of scientific strategies for Investigational Device Exemption, pre-market (First human use) and/or post-market evidence generation is required
  • Knowledge of Good Clinical Practice and 21 CFR medical device regulations, ISO 14155, Medical Device Regulation and other international regulations
  • Solid knowledge and background of clinical trials, study design and formal ICH/GCP knowledge and training
  • Proven leadership ability and track record; ability to interact with physicians and professionals inside and outside the company
  • Entrepreneurial and cooperative mindset; strategic thinker with excellent project management skills and ability to prioritize and plan
  • Prior experience in medical robotics, surgical or flexible catheter devices and operating room settings is heavily preferred
  • Results-driven, self-directed; able to work with minimal supervision
  • Excellent relational, verbal and written communication and presentation skills; strong relationship development and influence management
  • Must be able to travel up to 30-40 percent, including international travel
Responsibilities
  • Play a lead role in the development of the company’s clinical and scientific strategies, including clinical studies for new product development (first human use and/or IDE studies), post-market evidence generation or emerging markets for Endoluminal technology
  • Steer development and execution of clinical plans in aid of clinical trials to conform to applicable regulatory requirements (MDR, GCP or ISO 14155)
  • Provide strategic guidance to global clinical evidence strategy for the Endoluminal program with partnership with the business unit and GAVE representatives, including integrated evidence planning and execution for reimbursement submissions
  • Cross functional partnership with various key functions within the organization to shape external environment through interactions with notified bodies and regulatory agencies and external working groups
  • Translate strategic, corporate and technical content into clear evidence roadmap; create KPIs and 3-year evidence plans in aid of strategic initiatives for the Endoluminal Business Unit
  • Drive development and implementation of clinical research strategies to meet business goals and priorities; set up goals meaningful to the department and impactful to the organization
  • Accountable for year over year program budgets related to clinical trials
  • Provide leadership and direction to the broader Clinical Affairs team; address current and future opportunities to ensure sustainable success
  • Ensure compliance with corporate SOPs and regulatory requirements (GCP and US and OUS guidelines)
  • Provide solutions and improvements for departmental processes and standard operating procedures
  • Serve as subject matter expert in the literature landscape and clinical outcomes for Endoluminal procedures
  • Contribute to market intelligence relative to clinical outcomes for Intuitive and competitor technologies
  • Contribute to, review and approve key clinical documents and plans (Clinical Investigation Plans, Clinical Study Reports, Post-Market Clinical Follow-up plans)
  • As a functional manager, coach and guide team members in communication and aid direct reports in achieving goals, while promoting inclusion and diversity
Desired Qualifications
  • Prior experience in medical robotics, surgical or flexible catheter devices and operating room settings is heavily preferred

Intuitive Surgical designs, manufactures, and sells robotic surgical systems and provides related services and accessories for minimally invasive surgery. The core product helps surgeons perform operations with enhanced precision by guiding robotic arms controlled from a console, allowing procedures to be done through small incisions. Instruments and consumables are used with the systems and are supported by service contracts, creating a recurring revenue stream. Compared to competitors, Intuitive has a large installed base and focuses specifically on robotic-assisted surgery, combining devices, disposable instruments, and ongoing services to support hospitals and surgical centers. Its goal is to improve patient outcomes by enabling safer, less invasive procedures while expanding the use and capabilities of robotic surgery for more procedures and providers.

Company Size

10,001+

Company Stage

IPO

Headquarters

Sunnyvale, California

Founded

1995

Get referred to Intuitive Surgical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 19% to $2.89 billion, beating estimates on July 16.
  • Penang lease adds 316,000 square feet and 1,200 jobs, supporting Asia-Pacific growth.
  • Management kept 2026 da Vinci growth at 13.5%-15.5% and raised gross-margin guidance.

What critics are saying

  • FDA recall tracker listed multiple 2026 da Vinci Class II recalls, signaling quality-control strain.
  • Medtronic Hugo gained U.S. urology clearance in December 2025, tightening robotic-surgery competition.
  • 2027 extended instrument-use changes risk recurring revenue erosion if hospitals delay upgrades.

What makes Intuitive Surgical unique

  • Da Vinci installed base neared 13,000 systems worldwide, locking in switching costs.
  • Da Vinci 5 launched broadly in the U.S. in 2025, boosting utilization.
  • Ion procedures grew 36% in Q2 2026, extending Intuitive beyond soft-tissue robotics.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 19th, 2026
Abbott beats Q2 estimates with 13% sales growth as diagnostics surge 42%, while Intuitive Surgical posts 19% revenue rise

Abbott Laboratories reported strong fiscal Q2 2026 results, with sales rising 13% on a reported basis and 4.8% on a comparable basis, beating estimates and prompting the company to raise its annual profit forecast. The diagnostics segment was particularly strong, growing 42% to $3.09 billion, driven by its cancer diagnostics business following the Exact Sciences acquisition. Intuitive Surgical also exceeded expectations in Q2 2026, with revenue growing 19% to $2.89 billion and adjusted EPS of $2.80, beating forecasts by $0.30. The company placed 468 da Vinci units during the quarter, an 18% year-over-year increase, whilst maintaining a non-GAAP gross margin of 70.0%. The companies present contrasting investment cases: Abbott offers diversified healthcare portfolio resilience, whilst Intuitive Surgical relies on its robotic surgery ecosystem with recurring revenue comprising approximately 85% of total sales.

PR Newswire
Aug 17th, 2026
Intuitive leases 316,000-sq-ft facility in Penang to manufacture surgical instruments, create 1,200 jobs by 2032

Intuitive, the global leader in minimally invasive care and pioneer of robotic-assisted surgery, has signed a lease agreement with Penang Development Corporation for a new manufacturing facility in Malaysia. The 316,000-square-foot site in Bandar Cassia Technology Park will produce surgical instruments and electromechanical devices for Intuitive's da Vinci surgical system. The facility is expected to begin operations in 2028 and create 1,200 highly skilled jobs by 2032. The investment reflects Intuitive's commitment to Asia Pacific, where its da Vinci systems have treated more than 2.5 million patients across 13 markets over two decades. The expansion aims to support growing demand for robotic-assisted surgery across the region and strengthen Penang's position as a MedTech manufacturing hub in Southeast Asia.

Yahoo Finance
Aug 16th, 2026
Oppenheimer upgrades Intuitive Surgical to 'Outperform' with $500 price target

Oppenheimer upgraded Intuitive Surgical from "Perform" to "Outperform" with a $500 price target, implying a 24.6% upside. The analysts expect the medtech company to maintain its leading position in robotic surgery despite increasing competition. Intuitive reported strong Q2 results, with revenue rising 18.5% year-over-year to $2.89 billion, surpassing analyst expectations. Non-GAAP earnings per share climbed 27.9% to $2.80, beating the $2.50 estimate. The company placed 468 da Vinci surgical systems and 55 Ion endoluminal systems during the quarter. Combined da Vinci and Ion procedures rose approximately 16% globally. Wall Street maintains a "Strong Buy" consensus rating on the stock, with 22 of 31 analysts recommending a strong buy. The consensus price target of $480.93 represents a 19.85% upside.

Yahoo Finance
Aug 12th, 2026
Intuitive Surgical's valuation barely budges despite two years of growth forecasts

Intuitive Surgical trades at $401.23, down 32% from its 52-week high and 15% over twelve months. The stock currently trades at 37.7 times trailing adjusted earnings. Analysts forecast earnings of $12.08 per share by 2027, bringing the multiple down to 33 times — only 13% lower despite two years of growth. Consensus projects 7% annual earnings growth and 9.7% revenue growth, suggesting margin compression ahead. Management raised its 2026 gross profit margin guidance to 68-69%. However, the company plans to extend instrument use limits starting in the first half of 2027 to lower procedure costs and boost adoption. Intuitive has not finalised pricing for this programme, creating uncertainty around 2027 estimates. The company will quantify the impact on its next earnings call.

Yahoo Finance
Aug 8th, 2026
Medtronic and Intuitive Surgical lag market amid sector weakness

Medtronic and Intuitive Surgical, two medical device leaders, have underperformed this year due to sector weakness and company-specific challenges. However, both show potential for recovery. Medtronic's fourth-quarter revenue rose 9.9% to $9.8 billion, though adjusted earnings per share fell 4.3% to $1.55 due to higher costs, including tariffs. The company posted its highest annual revenue growth in a decade, driven partly by its Pulse Field Ablation franchise. Medtronic recently received FDA clearance for its Hugo robotic-assisted surgery system for urologic procedures, positioning it to compete in the underpenetrated robotic surgery market. The company plans to spin off its lower-margin diabetes care division, which should improve margins. With a 3.4% forward dividend yield and 49 consecutive years of payout increases, Medtronic appeals to income-focused investors.

INACTIVE